Limitations, agreements, and source contact

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib · Source last updated 2022-09-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

Eric.Padron@Moffitt.org

organization

H Lee Moffitt Cancer Center & Research Institute

phone

813-745-3907

title

Eric Padron, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice